Close Menu

Vela Diagnostics

The company is offering about 2.7 million units consisting of preferred stock and warrants at $8.80 per unit. 

The increase in C. diff sales resulted from an increase in the number of Great Basin's customers, it said. 

The company filed a prospectus to offer units comprising its Series E convertible preferred stock and Series C warrants.

The Salt Lake City-based MDx firm has initiated a clinical trial for its sample-to-result Staph identification/resistance test.

NEW YORK (GenomeWeb News) – Since its founding in 2005, molecular diagnostics firm Great Basin has raised $36 million in private financing, including about $9.6 million in a Series B round completed

NEW YORK (GenomeWeb News) — Great Basin said today that it has secured $9.5 million in Series B funding.

NEW YORK (GenomeWeb News) – Agilent Technologies said this week that it has appointed Ron Nersesian to be company president as well as chief operating officer, effective immediately.

Great Basin this week announced the opening of a new manufacturing facility for its recently launched molecular diagnostics system and first test.

Great Basin said that it has hired Lisa Weingartner as regional business manager for the southeast US region and Richard Corbiel as applications specialist.


The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.